Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer

被引：3
|
作者：
Teitelbaum, Ursina R. [1 ]
Haller, Daniel G. [1 ]
机构：
[1] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 05期
关键词：
CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED PHASE-III; THERAPY;
D O I：
10.1038/nrclinonc.2009.46
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. this paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.
引用
收藏
页码：250 / 251
页数：3
相关论文
共 50 条
  • [31] Sequencing Beyond the Second-Line Setting in Metastatic Colorectal Cancer
    Grothey, Axel
    Marshall, John L.
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (03)
  • [32] Management of metastatic colorectal cancer and indications of second-line chemotherapy
    Rougier, PP
    PRESSE MEDICALE, 1996, 25 (22): : 1004 - 1005
  • [33] Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
    Bai, Liangliang
    Zhang, Pengfei
    Zhou, Kexun
    Liao, Weiting
    Li, Qiu
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10419 - 10426
  • [34] Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer
    Kuboki, Yasutoshi
    Mizunuma, Nobuyuki
    Ozaka, Masato
    Ogura, Mariko
    Suenaga, Mitsukuni
    Shinozaki, Eiji
    Matsusaka, Satoshi
    Chin, Keishou
    Matsuura, Masaaki
    Hatake, Kiyohiko
    ONCOLOGY LETTERS, 2011, 2 (03) : 493 - 498
  • [35] Efficacy and toxicity of FOLFOX-4 as a second-line chemotherapy in locally advanced unresectable and metastatic carcinoma gall bladder: A prospective observational study.
    Dodagoudar, Chandragouda
    Mahanta, Anupam
    Goswami, Vikas
    Goel, Varun
    Doval, Dinesh C.
    Talwar, Vineet
    Batra, Ullas
    Singh, Sajjan
    Chauhan, Deepika
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Pharmacoeconomic analysis of XELOX versus FOLFOX for metastatic colorectal cancer first-line treatment in Taiwan
    Chen, H. -H.
    Chang, C. -S.
    Chen, L. -T.
    Chen, W. T. -L.
    Hsu, T. -C.
    Wang, J. -Y.
    ANNALS OF ONCOLOGY, 2015, 26 : 54 - 54
  • [37] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [38] Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study
    Bokemeyer, C.
    Bondarenko, I.
    Makhson, A.
    Hartmann, J. T.
    Aparicio, J.
    Zampino, M.
    Donea, S.
    Ludwig, H.
    Zubel, A.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer
    Cohen, Martin H.
    Gootenberg, Joe
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2007, 12 (03): : 356 - 361
  • [40] XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer
    Berk, Veli
    Ozdemir, Nuriye
    Ozkan, Metin
    Aksoy, Sercan
    Turan, Nedim
    Inal, Ali
    Balakan, Ozan
    Yasar, Nurgul
    Unal, Olcun Umit
    Benekli, Mustafa
    Durnali, Ayse
    Colak, Dilsen
    Sonmez, Ozlem Uysal
    HEPATO-GASTROENTEROLOGY, 2012, 59 (120) : 2635 - 2639
12345